JP6238969B2 - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP6238969B2
JP6238969B2 JP2015511669A JP2015511669A JP6238969B2 JP 6238969 B2 JP6238969 B2 JP 6238969B2 JP 2015511669 A JP2015511669 A JP 2015511669A JP 2015511669 A JP2015511669 A JP 2015511669A JP 6238969 B2 JP6238969 B2 JP 6238969B2
Authority
JP
Japan
Prior art keywords
edema
compound
treated
brain
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015511669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520151A (ja
JP2015520151A5 (enExample
Inventor
マーク・エフ・ペレティエ
ジョージ・ウィリアム・ファー
ポール・ロバート・マクガーク
クリストファー・エイチ・ホール
ウォルター・エフ・ボロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeromics Inc
Original Assignee
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Inc filed Critical Aeromics Inc
Publication of JP2015520151A publication Critical patent/JP2015520151A/ja
Publication of JP2015520151A5 publication Critical patent/JP2015520151A5/ja
Application granted granted Critical
Publication of JP6238969B2 publication Critical patent/JP6238969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015511669A 2012-05-08 2013-05-08 新規方法 Active JP6238969B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261644268P 2012-05-08 2012-05-08
US61/644,268 2012-05-08
US201261651778P 2012-05-25 2012-05-25
US61/651,778 2012-05-25
US201361799606P 2013-03-15 2013-03-15
US61/799,606 2013-03-15
PCT/US2013/040194 WO2013169939A2 (en) 2012-05-08 2013-05-08 New methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017210529A Division JP6570597B2 (ja) 2012-05-08 2017-10-31 新規方法

Publications (3)

Publication Number Publication Date
JP2015520151A JP2015520151A (ja) 2015-07-16
JP2015520151A5 JP2015520151A5 (enExample) 2016-06-23
JP6238969B2 true JP6238969B2 (ja) 2017-11-29

Family

ID=49551452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015511669A Active JP6238969B2 (ja) 2012-05-08 2013-05-08 新規方法
JP2017210529A Active JP6570597B2 (ja) 2012-05-08 2017-10-31 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017210529A Active JP6570597B2 (ja) 2012-05-08 2017-10-31 新規方法

Country Status (13)

Country Link
US (5) US9994514B2 (enExample)
EP (1) EP2846787B1 (enExample)
JP (2) JP6238969B2 (enExample)
KR (1) KR102200176B1 (enExample)
CN (2) CN104602682B (enExample)
AU (2) AU2013259526B2 (enExample)
BR (1) BR112014027983B1 (enExample)
CA (1) CA2872012C (enExample)
ES (1) ES2699646T3 (enExample)
IL (1) IL235512B (enExample)
MX (1) MX363473B (enExample)
RU (1) RU2671495C2 (enExample)
WO (1) WO2013169939A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
AU2014346682B2 (en) 2013-11-06 2020-03-12 Aeromics, Inc. Novel formulations
WO2016077787A1 (en) * 2014-11-13 2016-05-19 Aeromics, Llc Novel methods
JP2018500388A (ja) * 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
CZ2014915A3 (cs) * 2014-12-16 2016-02-24 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující
US10246733B2 (en) 2015-06-04 2019-04-02 Case Western University Assay and method for quantitating carbonic anhydrase activity and assessing red blood hemolysis
CN105030747B (zh) * 2015-07-03 2017-11-17 厦门大学 氯硝柳胺在制备防治近视药物中的应用
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
CA3022684A1 (en) * 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
CN109415363B (zh) 2016-05-18 2021-07-20 罗格斯，新泽西州立大学 用于治疗代谢疾病和癌症的新的线粒体解偶联剂
WO2018053807A1 (zh) * 2016-09-23 2018-03-29 深圳市中医院 氯硝柳胺乙醇胺盐在制备1型糖尿病药物中的应用
TWI631944B (zh) * 2016-10-14 2018-08-11 長庚大學 氯硝柳胺及其衍生物的用途
US11439869B2 (en) 2017-05-19 2022-09-13 Trudell Medical International Positive expiratory pressure device
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
US10945995B2 (en) * 2017-09-26 2021-03-16 Deha, Llc Compositions and methods for channelopathy disorders-targeting fluid movement across membranes
CN108203719A (zh) * 2017-12-26 2018-06-26 吉林医药学院 用于治疗视神经脊髓炎的小分子化合物及其高通量筛选方法
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
USD902947S1 (en) * 2019-03-25 2020-11-24 Apple Inc. Electronic device with graphical user interface
CN112107568B (zh) 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
IL300341A (en) * 2020-08-05 2023-04-01 Jiangsu Simcere Pharm Co Ltd A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도
EP4559520A1 (en) 2023-11-21 2025-05-28 Origenis GmbH Novel aqp4 inhibitors

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615511A (enExample) 1961-03-25
NL292958A (enExample) 1962-05-29 1900-01-01
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5137871A (en) * 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE4010536A1 (de) 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
US5137817A (en) 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
US5486530A (en) 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
DE4113820A1 (de) 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5858702A (en) 1991-12-13 1999-01-12 The Johns Hopkins University Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5)
US5741671A (en) 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US20060167110A1 (en) * 1995-01-13 2006-07-27 Blume Cherly D Methods for treating cerebrovascular disease by administering desmethylselegiline
EP0886471A4 (en) 1996-11-18 2002-07-17 Emisphere Tech Inc METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES
CA2298824A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
US5905090A (en) * 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6500809B1 (en) * 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
ATE257479T1 (de) * 1999-12-10 2004-01-15 Pfizer 5-ring heteroarylsubstituierte 1,4- dihydropyridine als bradykinin antagonisten
EP1847263A3 (en) 2000-12-18 2009-08-26 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
DK2438913T3 (da) 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
EA008622B1 (ru) 2002-06-05 2007-06-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы ассоциированной с иммунитетом протеинкиназы
EA009523B1 (ru) 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
EA008769B1 (ru) 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
TW200406198A (en) 2002-06-06 2004-05-01 Inst Med Molecular Design Inc O-substituted hydroxyaryl derivatives
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
AU2003242108B2 (en) 2002-06-10 2008-09-11 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of cancer
US20060089395A1 (en) 2002-06-10 2006-04-27 Susumu Muto Nf-kb activation inhibitors
CA2488979A1 (en) 2002-06-11 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of neurodegenerative diseases
KR20050019739A (ko) * 2002-06-11 2005-03-03 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 신경변성질환 치료제
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
EP1590458B1 (en) 2003-02-06 2012-10-31 Queen's University Of Belfast Bradykinin b2 receptor antagonist peptide from amphibian skin
NZ543201A (en) * 2003-05-01 2007-05-31 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
KR20060054308A (ko) 2003-07-16 2006-05-22 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 피부 색소침착의 치료제
ZA200603515B (en) 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US8467876B2 (en) * 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US20070254956A1 (en) 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
WO2005056020A2 (en) 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
ATE486606T1 (de) 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
KR20070111475A (ko) * 2005-01-04 2007-11-21 노파르티스 아게 만성 변비 환자에서 테가세로드의 효능을 확인하기 위한바이오마커
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
WO2007084464A2 (en) 2006-01-17 2007-07-26 The University Of North Carolina At Chapel Hill Water channel blockers and methods of use thereof
JP4273235B2 (ja) 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
AR061246A1 (es) 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
WO2007143689A2 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008067196A2 (en) 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
US20080171719A1 (en) 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US20080214486A1 (en) 2006-11-28 2008-09-04 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
DK2118279T3 (en) * 2007-01-16 2018-02-26 Ipintl Llc HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
WO2008098160A1 (en) 2007-02-09 2008-08-14 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
CN105123670B (zh) 2007-02-17 2018-12-14 哈佛学院董事会 用于进行组织保存的组合物以及方法
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
CN101842095B (zh) 2007-07-02 2015-06-24 于明 肿瘤治疗的配方,方法和靶目标
RU2010120675A (ru) 2007-10-23 2011-11-27 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор продуцирования pai-1
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
JP5812318B2 (ja) 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ， インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
GB0724340D0 (en) 2007-12-13 2008-01-30 Univ Dundee Novel Therapeutic Agents
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20090286799A1 (en) * 2008-05-16 2009-11-19 Zhi-Gang Jiang Methods for the treatment of brain edema
US20110263478A1 (en) 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
US20120010178A1 (en) 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
JP5778583B2 (ja) * 2009-01-12 2015-09-16 バギ リサーチ リミテッド 炎症を治療するためおよび免疫応答を調節するための化合物ならびにそれらの使用
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
US20130053318A1 (en) * 2010-03-10 2013-02-28 Parry Laura Modulating aquaporins with relaxin
KR20180123176A (ko) 2010-07-19 2018-11-14 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
WO2012013567A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012125749A2 (en) 2011-03-14 2012-09-20 Io Therapeutics, Inc. INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS
DK2717883T3 (en) 2011-05-02 2017-04-24 Stichting Vumc PROTECTION AGAINST ENDOTELIAL BARRIER DYSFUNCTION BY INHIBITION OF THE TYROSINKINASE ABL RELATED GENES (ARG)
RU2461375C1 (ru) 2011-05-19 2012-09-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ комбинированного лечения больных местно-распространенным раком желудка
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
CN105636583B (zh) 2013-09-13 2019-08-20 板井昭子 水溶液制剂及其制造方法
AU2014346682B2 (en) 2013-11-06 2020-03-12 Aeromics, Inc. Novel formulations
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
WO2016077787A1 (en) 2014-11-13 2016-05-19 Aeromics, Llc Novel methods
AU2016271576B2 (en) 2015-05-29 2021-10-07 Biogen Chesapeake, Llc Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
JP7349786B2 (ja) 2015-10-07 2023-09-25 バイオジェン チェサピーク エルエルシー Ｃｎｓ浮腫に関連する損傷または状態を処置する方法
CA3022684A1 (en) 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
EP4483955A3 (en) 2016-07-29 2025-03-12 Remedy Pharmaceuticals, Inc. Methods of medical treatment with sur1-trpm4 channel inhibitors
IL300341A (en) 2020-08-05 2023-04-01 Jiangsu Simcere Pharm Co Ltd A pharmaceutical composition of an aquaporin inhibitor and a method for its preparation

Also Published As

Publication number Publication date
AU2018203357C1 (en) 2020-06-25
US11873266B2 (en) 2024-01-16
MX363473B (es) 2019-03-25
CN104602682A (zh) 2015-05-06
US20240360077A1 (en) 2024-10-31
US20220081391A1 (en) 2022-03-17
IL235512A0 (en) 2015-01-29
CN104602682B (zh) 2018-12-14
US20180334424A1 (en) 2018-11-22
US20150342967A1 (en) 2015-12-03
US20150133405A1 (en) 2015-05-14
US12503425B2 (en) 2025-12-23
US9573885B2 (en) 2017-02-21
ES2699646T3 (es) 2019-02-12
IL235512B (en) 2018-06-28
RU2671495C2 (ru) 2018-11-01
BR112014027983A2 (pt) 2017-06-27
JP2015520151A (ja) 2015-07-16
AU2013259526B2 (en) 2018-02-15
MX2014013639A (es) 2015-08-20
CA2872012A1 (en) 2013-11-14
KR102200176B1 (ko) 2021-01-11
EP2846787A4 (en) 2015-11-11
WO2013169939A3 (en) 2014-02-13
JP6570597B2 (ja) 2019-09-04
CA2872012C (en) 2017-06-20
BR112014027983B1 (pt) 2022-05-24
EP2846787A2 (en) 2015-03-18
RU2014148984A (ru) 2016-06-27
US11084778B2 (en) 2021-08-10
JP2018016647A (ja) 2018-02-01
AU2018203357A1 (en) 2018-05-31
KR20150035566A (ko) 2015-04-06
US9994514B2 (en) 2018-06-12
CN109512805B (zh) 2021-12-31
CN109512805A (zh) 2019-03-26
AU2018203357B2 (en) 2020-01-30
AU2013259526A1 (en) 2014-12-18
EP2846787B1 (en) 2018-08-29
WO2013169939A2 (en) 2013-11-14
HK1208363A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
JP6570597B2 (ja) 新規方法
JP2016535787A (ja) 新規方法
JP5707489B2 (ja) １型糖尿病の処置
CN104869993B (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
US20140221286A1 (en) Sodium channel blockers reduce glucagon secretion
KR20200006595A (ko) 심부전 치료를 위한 포르밀 펩티드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 효능제의 신규 용도
EP2882431B1 (en) Probenecid for treating decompensated heart failure
US20010003751A1 (en) Pharmaceutical composition for treating transient ischemic attack
US20240262916A1 (en) Methods and compositions for treating cardiovascular disease
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases
EP4561574A1 (en) Dosing regimen for a nlrp3 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160506

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171031

R150 Certificate of patent or registration of utility model

Ref document number: 6238969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250